Acadia Pharmaceuticals Reports Strong Q4 & Full Year 2025 Results, Exceeds $1B Revenue, and Issues Positive 2026 Guidance

summarizeSummary

Acadia Pharmaceuticals announced strong Q4 and full year 2025 financial results, exceeding $1 billion in annual revenue, and issued positive revenue guidance for 2026, alongside updates on product launches and pipeline progress.

check_boxKey Events

• Strong Q4 and Full Year 2025 Financial Performance

  Reported Q4 2025 GAAP total revenues of $284 million (up 9% YoY) and full year 2025 GAAP total revenues of $1.07 billion (up 12% YoY), marking the first time the company surpassed $1 billion in annual revenue. Net income for Q4 2025 was $274 million ($1.60 diluted EPS), significantly up from $144 million in Q4 2024, partly due to a $250 million non-cash income tax benefit.

• Positive Full Year 2026 Revenue Guidance

  Issued full year 2026 guidance for total revenues in the range of $1.22 to $1.28 billion, including NUPLAZID net sales of $760 to $790 million and DAYBUE net sales of $460 to $490 million, reflecting continued growth expectations.

• IRA Rebate Accounting Clarification

  Disclosed a non-recurring $20 million change in estimate for NUPLAZID IRA rebate accruals, impacting GAAP net sales. The company provided non-GAAP adjusted figures to highlight underlying strong commercial performance, with NUPLAZID volume growing 13% in Q4 2025 and 9% for the full year.

• Pipeline and Product Development Updates

  Announced that DAYBUE STIX powder formulation has shipped to the first patient, with a broader launch planned for early Q2 2026. Top-line results from the remlifanserin Phase 2 RADIANT study in Alzheimer's disease psychosis remain on track for August to October 2026.

auto_awesomeAnalysis

Acadia Pharmaceuticals reported robust financial results for the fourth quarter and full year 2025, surpassing $1 billion in annual revenue for the first time. The company demonstrated strong year-over-year growth in both GAAP and non-GAAP adjusted revenues for its key products, NUPLAZID and DAYBUE. Management provided positive revenue guidance for full year 2026, indicating continued growth expectations. The filing also clarified a non-recurring accounting adjustment related to IRA inflation cap rebates for NUPLAZID, emphasizing that underlying commercial performance remains strong. Additionally, updates on the DAYBUE STIX launch and the timeline for Phase 2 remlifanserin study results provide future catalysts for the company.